SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
FRA:SRT3 - Deutsche Boerse Ag - DE0007165631 - Currency: EUR
SRT3 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 17 industry peers in the Life Sciences Tools & Services industry. SRT3 may be in some trouble as it scores bad on both profitability and health. SRT3 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SRT3 was profitable.
SRT3 had a positive operating cash flow in the past year.
SRT3 had positive earnings in each of the past 5 years.
In the past 5 years SRT3 always reported a positive cash flow from operatings.
1.2 Ratios
SRT3 has a Return On Assets of 0.94%. This is in the lower half of the industry: SRT3 underperforms 76.47% of its industry peers.
SRT3 has a Return On Equity of 3.52%. This is in the lower half of the industry: SRT3 underperforms 70.59% of its industry peers.
With a Return On Invested Capital value of 3.51%, SRT3 is not doing good in the industry: 76.47% of the companies in the same industry are doing better.
SRT3 had an Average Return On Invested Capital over the past 3 years of 8.34%. This is in line with the industry average of 6.91%.
The 3 year average ROIC (8.34%) for SRT3 is well above the current ROIC(3.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.94% | ||
| ROE | 3.52% | ||
| ROIC | 3.51% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
With a Profit Margin value of 2.77%, SRT3 is not doing good in the industry: 76.47% of the companies in the same industry are doing better.
In the last couple of years the Profit Margin of SRT3 has declined.
SRT3 has a Operating Margin of 11.82%. This is in the lower half of the industry: SRT3 underperforms 64.71% of its industry peers.
SRT3's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 45.27%, SRT3 is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
SRT3's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.82% | ||
| PM (TTM) | 2.77% | ||
| GM | 45.27% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SRT3 is still creating some value.
Compared to 1 year ago, SRT3 has more shares outstanding
The number of shares outstanding for SRT3 has been increased compared to 5 years ago.
Compared to 1 year ago, SRT3 has an improved debt to assets ratio.
2.2 Solvency
SRT3 has an Altman-Z score of 2.19. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
SRT3 has a Altman-Z score of 2.19. This is in the lower half of the industry: SRT3 underperforms 64.71% of its industry peers.
The Debt to FCF ratio of SRT3 is 6.50, which is on the high side as it means it would take SRT3, 6.50 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 6.50, SRT3 is not doing good in the industry: 70.59% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.55 is on the high side and indicates that SRT3 has dependencies on debt financing.
SRT3 has a worse Debt to Equity ratio (1.55) than 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.55 | ||
| Debt/FCF | 6.5 | ||
| Altman-Z | 2.19 |
ROIC/WACC0.47
WACC7.42%
2.3 Liquidity
SRT3 has a Current Ratio of 1.46. This is a normal value and indicates that SRT3 is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of SRT3 (1.46) is comparable to the rest of the industry.
SRT3 has a Quick Ratio of 1.46. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.93, SRT3 is doing worse than 76.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.46 | ||
| Quick Ratio | 0.93 |
3. Growth
3.1 Past
SRT3 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.23%.
The earnings per share for SRT3 have been decreasing by -11.87% on average. This is quite bad
Looking at the last year, SRT3 shows a small growth in Revenue. The Revenue has grown by 3.99% in the last year.
SRT3 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.10% yearly.
EPS 1Y (TTM)-36.23%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%30.97%
Revenue 1Y (TTM)3.99%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%7.74%
3.2 Future
SRT3 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.69% yearly.
The Revenue is expected to grow by 8.89% on average over the next years. This is quite good.
EPS Next Y22.89%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
EPS Next 5Y19.69%
Revenue Next Year6.37%
Revenue Next 2Y7.98%
Revenue Next 3Y8.7%
Revenue Next 5Y8.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 50.21, SRT3 can be considered very expensive at the moment.
Based on the Price/Earnings ratio, SRT3 is valued a bit more expensive than 70.59% of the companies in the same industry.
When comparing the Price/Earnings ratio of SRT3 to the average of the S&P500 Index (26.91), we can say SRT3 is valued expensively.
With a Price/Forward Earnings ratio of 33.79, SRT3 can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a slightly more expensive valuation: SRT3 is more expensive than 64.71% of the companies listed in the same industry.
SRT3's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.21 | ||
| Fwd PE | 33.79 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SRT3 is valued a bit more expensive than 64.71% of the companies in the same industry.
SRT3's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.54 | ||
| EV/EBITDA | 23.77 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SRT3 does not grow enough to justify the current Price/Earnings ratio.
SRT3's earnings are expected to grow with 26.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.19
PEG (5Y)N/A
EPS Next 2Y24.43%
EPS Next 3Y26.21%
5. Dividend
5.1 Amount
With a yearly dividend of 0.42%, SRT3 is not a good candidate for dividend investing.
SRT3's Dividend Yield is comparable with the industry average which is at 0.74.
Compared to an average S&P500 Dividend Yield of 2.43, SRT3's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.42% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
53.09% of the earnings are spent on dividend by SRT3. This is a bit on the high side, but may be sustainable.
SRT3's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP53.09%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
FRA:SRT3 (6/25/2025, 4:51:51 PM)
214.4
+0.2 (+0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.05B
Analysts77.14
Price Target360.76 (68.26%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.42% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP53.09%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.1%
Min EPS beat(2)-4.13%
Max EPS beat(2)-4.06%
EPS beat(4)1
Avg EPS beat(4)-0.94%
Min EPS beat(4)-22.4%
Max EPS beat(4)26.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.77%
Min Revenue beat(2)2.67%
Max Revenue beat(2)4.87%
Revenue beat(4)3
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-4.07%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.85%
PT rev (3m)-4.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.21 | ||
| Fwd PE | 33.79 | ||
| P/S | 4.66 | ||
| P/FCF | 22.54 | ||
| P/OCF | 15 | ||
| P/B | 5.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.77 |
EPS(TTM)4.27
EY1.99%
EPS(NY)6.35
Fwd EY2.96%
FCF(TTM)9.51
FCFY4.44%
OCF(TTM)14.29
OCFY6.66%
SpS45.99
BVpS36.19
TBVpS-35.83
PEG (NY)2.19
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.94% | ||
| ROE | 3.52% | ||
| ROCE | 4.72% | ||
| ROIC | 3.51% | ||
| ROICexc | 3.9% | ||
| ROICexgc | 12.82% | ||
| OM | 11.82% | ||
| PM (TTM) | 2.77% | ||
| GM | 45.27% | ||
| FCFM | 20.68% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexcg growth 3Y-35.26%
ROICexcg growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.55 | ||
| Debt/FCF | 6.5 | ||
| Debt/EBITDA | 5.06 | ||
| Cap/Depr | 84.42% | ||
| Cap/Sales | 10.39% | ||
| Interest Coverage | 1.93 | ||
| Cash Conversion | 128.78% | ||
| Profit Quality | 745.86% | ||
| Current Ratio | 1.46 | ||
| Quick Ratio | 0.93 | ||
| Altman-Z | 2.19 |
F-Score7
WACC7.42%
ROIC/WACC0.47
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-36.23%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%30.97%
EPS Next Y22.89%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
EPS Next 5Y19.69%
Revenue 1Y (TTM)3.99%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%7.74%
Revenue Next Year6.37%
Revenue Next 2Y7.98%
Revenue Next 3Y8.7%
Revenue Next 5Y8.89%
EBIT growth 1Y-9.05%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year103.14%
EBIT Next 3Y38.58%
EBIT Next 5Y27.44%
FCF growth 1Y303.11%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y44.89%
OCF growth 3Y4.07%
OCF growth 5Y20.79%